Digital Twins as Synthetic Controls in Single-Arm Trials

• URL: http://arxiv.org/abs/2605.12832v1
• Date: Tue, 12 May 2026 23:58:48 GMT
• Title: Digital Twins as Synthetic Controls in Single-Arm Trials
• Abstract summary: We argue that outcome-model-based synthetic control arms are an important tool for single-arm trials.<n>We focus on digital twins, personalized predictions of disease progression generated from machine learning models trained on historical datasets.
• Score: 0.0
• License: http://arxiv.org/licenses/nonexclusive-distrib/1.0/
• Abstract: Single-arm trials are an important study design for evaluating drug efficacy and safety without enrolling patients into a control arm. Although they do not provide the gold-standard evidence of randomized controlled trials, they are increasingly used in clinical development as they offer an efficient, ethical, and practical alternative. A wide variety of approaches can be used to construct control comparators and estimate treatment effects, from fixed comparators informed by clinical knowledge to data-based and model-based patient-level comparators, also known as synthetic controls. Powerful and flexible machine learning models can allow outcome-model-based synthetic controls to overcome key limitations of direct data-based approaches, yield more robust estimates of treatment effects, and provide a principled way to incorporate corrections or encode additional assumptions when external data are not directly comparable. In this work, we argue that outcome-model-based synthetic control arms are an important tool for single-arm trials. We focus on digital twins, personalized predictions of disease progression generated from machine learning models trained on historical datasets, which naturally leverage these flexible approaches. We review doubly robust estimators, present power and sample size formulas, and discuss trade-offs in selecting historical data for training and analysis. We also outline practical considerations for deploying digital twins within the framework of recent FDA draft guidance on the use of artificial intelligence in drug development. Finally, we reanalyze data from trials in amyotrophic lateral sclerosis and Huntington's disease to demonstrate the proposed methods.

Related papers

• FRESH: Information-Geometric Calibration of Patient-Level Models to Aggregate Evidence [0.0]
  Fresh is a method for incorporating population-level summary results into predictive models trained on patient-level data.<n>The method produces patient-level predictions from a re-calibrated model that matches a set of specified aggregate statistics for a target population.
  arXiv  Detail & Related papers  (2026-05-15T17:50:11Z)
• Machine learning models for estimating counterfactuals in a single-arm inflammatory bowel disease study [1.685177132716279]
  Single-arm trials accelerate study timelines by reducing the number of patients that must be recruited for a concurrent control group.<n>One approach is to construct a virtual control arm using a machine learning (ML) model trained on external control data to predict the counterfactual outcomes of the treatment arm.<n>Our study supports virtual controls as a viable and effective substitute for expensive, lengthy or unethical patient recruitment in an inflammatory bowel disease (IBD) trial.
  arXiv  Detail & Related papers  (2026-04-25T23:09:07Z)
• Eliciting Medical Reasoning with Knowledge-enhanced Data Synthesis: A Semi-Supervised Reinforcement Learning Approach [62.0906177191353]
  Existing approaches distill chain-of-thought reasoning traces from large proprietary models via supervised fine-tuning, then conduct reinforcement learning (RL)<n>We propose MedSSR, a Medical Knowledge-enhanced data Synthesis and Semi-supervised Reinforcement learning framework.<n>Our framework first employs rare disease knowledge to synthesize distribution-controllable reasoning questions.<n>We then utilize the policy model itself to generate high-quality pseudo-labels. This enables a two-stage, intrinsic-to-extrinsic training paradigm: self-supervised RL on the pseudo-labeled data, followed by supervised RL on the human-annotated real data
  arXiv  Detail & Related papers  (2026-04-13T14:37:38Z)
• Predicting Neuromodulation Outcome for Parkinson's Disease with Generative Virtual Brain Model [95.41752463487008]
  Parkinson's disease affects over ten million people worldwide.<n>Inter-individual variability limits empirical treatment selection, increasing non-negligible surgical risk and cost.<n>We bridge this gap with a pretraining-finetuning framework to predict outcomes directly from resting-state fMRI.
  arXiv  Detail & Related papers  (2026-03-31T02:36:10Z)
• Toward Valid Generative Clinical Trial Data with Survival Endpoints [4.7846041866823965]
  Existing generative approaches, largely GAN-based, are data-hungry, unstable, and rely on strong assumptions such as independent censoring.<n>We introduce a variational autoencoder (VAE) that jointly generates mixed-type co variables and survival outcomes within a unified latent variable framework, without assuming independent censoring.<n>Our method outperforms GAN baselines on fidelity, utility, and privacy metrics, while revealing systematic miscalibration of type I error and power.
  arXiv  Detail & Related papers  (2025-11-20T17:03:38Z)
• Improving the Generation and Evaluation of Synthetic Data for Downstream Medical Causal Inference [89.5628648718851]
  Causal inference is essential for developing and evaluating medical interventions.<n>Real-world medical datasets are often difficult to access due to regulatory barriers.<n>We present STEAM: a novel method for generating Synthetic data for Treatment Effect Analysis in Medicine.
  arXiv  Detail & Related papers  (2025-10-21T16:16:00Z)
• The Framework That Survives Bad Models: Human-AI Collaboration For Clinical Trials [2.6377299508948746]
  Using AI as a supporting reader (AI-SR) is the most suitable approach for clinical trials, as it meets all criteria across various model types, even with bad models.<n>This method consistently provides reliable disease estimation, preserves clinical trial treatment effect estimates and conclusions, and retains these advantages when applied to different populations.
  arXiv  Detail & Related papers  (2025-10-08T01:40:41Z)
• CATE Estimation With Potential Outcome Imputation From Local Regression [24.97657507206549]
  We propose a model-agnostic data augmentation method for Conditional Average Treatment Effect estimation.<n>Inspired by this idea, we propose a contrastive learning approach that reliably imputes missing potential outcomes.<n>We provide both theoretical guarantees and extensive numerical studies demonstrating the effectiveness of our approach.
  arXiv  Detail & Related papers  (2023-11-07T00:36:51Z)
• TREEMENT: Interpretable Patient-Trial Matching via Personalized Dynamic Tree-Based Memory Network [54.332862955411656]
  Clinical trials are critical for drug development but often suffer from expensive and inefficient patient recruitment. In recent years, machine learning models have been proposed for speeding up patient recruitment via automatically matching patients with clinical trials. We introduce a dynamic tree-based memory network model named TREEMENT to provide accurate and interpretable patient trial matching.
  arXiv  Detail & Related papers  (2023-07-19T12:35:09Z)
• A Causal Inference Framework for Leveraging External Controls in Hybrid Trials [1.7942265700058988]
  We consider the challenges associated with causal inference in settings where data from a randomized trial is augmented with control data from an external source. We propose estimators, review efficiency bounds, and an approach for efficient doubly-robust estimation. We apply the framework to a trial investigating the effect of risdisplam on motor function in patients with spinal muscular atrophy.
  arXiv  Detail & Related papers  (2023-05-15T19:15:32Z)
• Drug Synergistic Combinations Predictions via Large-Scale Pre-Training and Graph Structure Learning [82.93806087715507]
  Drug combination therapy is a well-established strategy for disease treatment with better effectiveness and less safety degradation. Deep learning models have emerged as an efficient way to discover synergistic combinations. Our framework achieves state-of-the-art results in comparison with other deep learning-based methods.
  arXiv  Detail & Related papers  (2023-01-14T15:07:43Z)
• Benchmarking Heterogeneous Treatment Effect Models through the Lens of Interpretability [82.29775890542967]
  Estimating personalized effects of treatments is a complex, yet pervasive problem. Recent developments in the machine learning literature on heterogeneous treatment effect estimation gave rise to many sophisticated, but opaque, tools. We use post-hoc feature importance methods to identify features that influence the model's predictions.
  arXiv  Detail & Related papers  (2022-06-16T17:59:05Z)

This list is automatically generated from the titles and abstracts of the papers in this site.

This site does not guarantee the quality of this site (including all information) and is not responsible for any consequences.